The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
Information source: Bayer
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Pritor (Telmisartan , BAY68-9291) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
The main purpose of this study is to asses the efficacy and safety of telmisartan, with the
special attention on the influence of telmisartan on selected metabolic parameters of
patients.
Clinical Details
Official title: A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients
Study design: Cohort, Prospective
Primary outcome: Efficacy and safety of the treatment with telmisartan reported by the physician
Secondary outcome: Changes in metabolic parameters in telmisartan treated patients
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age over 18
- Untreated or ineffectively treated arterial hypertension
Exclusion Criteria:
- Cholestatic disorders and severe hepatic failure
- Allergy to telmisartan
- Pregnancy and lactation period
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, Croatia; Recruiting
Many Locations, Poland; Completed
Many Locations, Slovakia; Completed
Many Locations, Slovenia; Completed
Additional Information
Click here and search for drug information provided by the FDA Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product Click here to find results for studies related to marketed products
Starting date: September 2006
Ending date: October 2009
Last updated: October 9, 2009
|
